Management Team
Our management team consists of experienced leaders who share a genuine passion for improving global health. With a proven track record in strategy, operations, and clinical trial delivery, they provide the expertise and guidance to deliver high‑quality, patient‑centered solutions.
By championing innovative approaches and building relationships with scientific leaders, our management team drives the continued advancement of our capabilities, ensuring our partners receive the very best outcomes and support.
Mary Gunn PhD, MBA, MA, LLM
With over three decades of experience, Dr Gunn has held pivotal roles in leading biotech firms and academic institutions including Pfizer, Crucell (Johnson & Johnson), Becton Dickson, Clintec (IQVIA), ICON, and Health Decisions (Premier Research). She is a corporate strategy expert with extensive experience in life science corporate development, strategic partnerships, co-development, licensing partnerships, M&A and post-merger integrations. She is renowned for her extensive contributions to medical research, innovative drug development, contract research and clinical trials, and has spearheaded the development of several FDA-approved drugs, particularly in the CNS and vaccines domains. She is passionate about market access to innovation.
Tony Proctor CPA
With over 25 years of financial leadership experience, Tony Proctor has held pivotal roles at Lexitas, Parexel, and Syneos Health. He is an expert in financial strategy, corporate finance, M&A, global systems integration, and private equity partnerships. Tony has driven transformative growth through organic revenue acceleration, operational excellence, and the implementation of best-in-class financial practices.
Renowned for his ability to align financial strategies with organizational objectives, Tony has led major organizational upgrades and spearheaded impactful M&A processes. He is committed to advancing operational efficiency and supporting George Clinical’s mission to improve health outcomes through innovative clinical research. A Certified Public Accountant, Tony holds an MBA in Finance and is passionate about delivering sustainable growth.
Michael Bishop
As the Chief Commercial Officer, Michael leads the US, Europe, and APAC business development teams, along with proposal and contracting groups. He brings over 30 years of business development and life sciences experience with companies including Cardinal Health, PPD, ICON, and, most recently, Ergomed/PrimeVigilance. Over the last 16+ years, Michael has led various CRO commercial teams including those in business development and global strategic accounts driving business strategy for large pharma and biotech companies. He also has a strong background in supporting strategic partnerships, proposal development, inside sales, and sales training and development.
Maria Ali MBBS, MBA
Maria serves as the Chief Medical Officer for George Clinical, responsible for continuing to build the organization’s enviable network of investigators and scientific leaders. Previously, she led the medical and safety services group at George Clinical who provide safety management, endpoint adjudication, medical monitoring and scientific leadership for both commercially sponsored and academic clinical trials. Maria has worked closely with the scientific leads at the George Institute to develop and implement scientific leadership models for George Clinical studies, as well as to develop new ideas for clinical research, and processes to improve clinical trial design and efficiencies. Maria has several years’ experience in both public health and clinical research as well as research management across a range of settings including hospitals, academic and clinical research organizations.
Jing Ping Yeo PhD
Jing Ping oversees operational delivery for studies conducted globally and heads the project operations group. She also provides oversight to key accounts at governance levels. With almost three decades of leadership and management experience, she has overseen all aspects of a startup’s operations in Asia Pacific and led a global biopharmaceutical unit with multi-compound, multi-therapeutic portfolios. Her research expertise spans budgetary management, clinical drug development, clinical operations, project management, biometrics, medical writing, medical affairs and quality management. Currently, she serves as the Steering Committee Member for the of Drug Information Association (DIA), is the Program Committee for DIA-Asia and chairs the Singapore Clinical Research Professionals Association.
Zhenfei Yin MD
As Country Head, China, Zhenfei is responsible for leading the operations teams across China. Zhenfei Yin brings with him more than 17 years of substantial industry experience leading Project Management, Clinical Operations, and Business Development teams across the CRO and Pharmaceutical sectors. Before joining George Clinical as China country head, he worked in several global CROs and pharmaceuticals, including ICON, Wuxi AppTec, IQVIA, and Sanofi. His successfully led team completed more than 120 Phase I – IV clinical trials, most of which are global studies (Asia Pacific, Australia and the United States), covering different Therapeutic Area, including: Oncology, Cardiovascular, Central nervous system, Endocrine, Infectious diseases, Urology, Respiratory diseases, and medical devices/IVDs. He has Master Degree of Urology from Peking University 1st Hospital.
Abby Abraham MPharm
Abby Abraham serves as the Global Head of Data Science for George Clinical. Abby is responsible for developing new capabilities in data science and operations and enabling continued growth of Data management in the organization. He brings a combination of significant experience in clinical operations, leveraging data for operational effectiveness, and adopting new technologies to enable the organizational transition to new and emerging paradigms of clinical trial execution. His experience in business operations, strategy, and new technology adoption enable George Clinical to pursue innovation-led growth. In addition to his responsibilities in Data Science, he is also the Country Head of India business operations.
Louise Brnabic PhD
Louise Brnabic, Global Head, Quality, and is responsible for providing quality management support for all functional areas and countries, ensuring that global standards are maintained in all clinical trial-related activities. With a background in biochemical research, Louise has 20 years’ experience in quality management, project management, and clinical operations. She has worked with pharmaceutical and device companies, across all study phases and in a wide range of therapeutic areas.
Harmony Chan MBA
Harmony leads the Human Resources (HR) team globally to effectively partner with the organization to deliver on its people and company objectives. Harmony has over 15 years of talent acquisition and generalist HR experience across the Life Sciences, IT&T and Built Environment industries globally and is MBA qualified in addition to holding a BA (Organizational Learning) and being Training & Assessment certified.
Scientific Leadership Team
For core therapeutic areas of expertise, we are able to provide scientific advisory support of the highest caliber through our Scientific Advisory Committee. This Committee is composed of key opinion leaders who have deep clinical trial experience and are also engaged in patient care through clinical activities, therefore their advice encompasses both scientific elements and pragmatic ones based on real-world scenarios.
Jonathan Barratt PhD, FRCP
Professor Barratt focuses on glomerular disease, multi-system renal disease and complications of CKD, in particular renal associated anemia. He is The Mayer Professor of Renal Medicine & Honorary Consultant Nephrologist and leads the Renal Research Group within the College of Life Sciences University of Leicester, UK. He is the IgA nephropathy Rare Disease Group lead for the UK National Registry of Rare Kidney Diseases (RaDaR) and a member of the steering committee for the International IgA Nephropathy Network.
Ralph Boccia MD, FACP
Dr. Boccia is Medical Director of the Center for Cancer and Blood Disorders in Bethesda, Maryland, and Clinical Associate Professor of Medicine at Georgetown University in Washington, DC. He also serves as the Chief Medical Officer for the International Oncology Network (ION). He conducts research in exploring the latest advances in cancer treatment and offers individualized care to patients with focus on multi-modal treatment regimens.
Chee Kay Cheung PhD, FRCP
Dr. Cheung is a Consultant Nephrologist and Honorary Senior Lecturer, University of Leicester, UK. His PhD examined factors that contribute towards progressive kidney damage in IgA nephropathy (IgAN), and his current interests focus on clinical trials in this condition. He leads a number of investigator-initiated studies in collaboration with industry and academic partners, and has served as UK national chief investigator and principal investigator on multiple IgAN clinical trials. He leads specialist clinics in glomerular diseases and in vasculitis and lupus nephritis. He is a steering committee member and active member of several national working groups, including the UK IgAN rare diseases group and the UK glomerular diseases clinical studies group.
Mustafa Khasraw MBChB, MD, FRACP, FRCP
Dr. Khasraw’s is a neuro-oncologist, professor of medicine and Deputy Director of the Center for Cancer Immunotherapy at Duke University, USA. He is interested in translating research into new therapies and at Duke, is tasked with speeding up clinical research and translation for scientists across all departments and tumor sites. He leads several clinical and translational programs with significant laboratory collaborations and is the principal investigator on first-in-human Phase I immunotherapy clinical trials in solid tumors. His research interests include biomarker development and design of innovative clinical trials to improve outcomes for patients with primary and metastatic cancers of the central nervous systems.
Herbert H. Loong MBBS, PDipMDPath, MRCP (UK), FRCP Edin, FHKCP, FHKAM (Medicine)
Sradha Kotwal BhB, MBChB, FRACP, GradD Dip (Clin Epi), PhD
Dr. Kotwal is a clinical nephrologist at Prince of Wales Hospital in Sydney Australia, Program Head of the Renal and metabolic division at The George Institute for Global Health and a senior clinical lecturer at the University of NSW. She is the principal investigator for the Glomerular Disease Registry and Biobank in Sydney and the Global Kidney Patients Trial Network (GKPTN). Her main interests include novel and pragmatic clinical trials and she is passionate about increasing clinical trial access for patients with kidney disease together with increasing personalized medicine capacity in Australia.
Roberto Pecoits-Filho MD, PhD, FACP, FASN
Dr. Pecoits-Filho is a practicing Nephrologist and clinical investigator focused on evolving the way CKD patients are treated in day-to-day clinical practice by integrating observational research with clinical trials. He is the Scientific Director of the DOPPS program at Arbor Research Collaborative for Health, Michigan, and a professor of Medicine at the Pontifical Catholic University of Paraná, Brazil.
Gillian Ryan
Gillian Ryan is Global Head of Early Phase at George Clinical. She has over 20 years of clinical research experience across all phases of global and local research activities including specializing in the operational conduct of Phase I studies in healthy volunteer and patient populations. Gillian has proven skills in managing and overseeing the conduct of niche and complex studies across all phases and involving multiple sites and countries to ensure study delivery within scope, timelines and budget.
David Thomas PhD, FRACP (Medical Oncology)
Professor Thomas’ research focus is on the application of genomic technologies to the understanding and management of cancer. He is the inaugural Director, Centre for Molecular Oncology, University of New South Wales; Head of the Genomic Cancer Medicine Laboratory, Garvan Institute of Medical Research; and CEO of Omico. He founded the Australasian Sarcoma Study Group and established Australia’s leading adolescent and young adult cancer unit at the Peter MacCallum Cancer Centre. Professor Thomas leads the International Sarcoma Kindred Study and led the first international study of denosumab in Giant Cell Tumor of bone, leading to FDA and TGA approval.
Hernán Trimarchi MD, PHD, FACP, FASN
Dr. Trimarchi focuses on glomerular diseases, particularly in proteinuria and podocyturia, IgA nephropathy, focal and segmental glomerulosclerosis, lupus nephritis and Fabry disease. He is Head of the Division of Nephrology and Renal Transplantation at the Hospital Británico de Buenos Aires and a member of the Steering Committee of the International IgA Nephropathy Network. He is involved in many clinical research protocols related to glomerular diseases and CKD as member of the advisory board and Steering Committee, as KOL or national coordinator.
Ari VanderWalde MD, MPH, MBioeth, FACP
Dr. VanderWalde specializes in melanoma and is experienced in genomic tumor assessment, public health, tumor immunotherapy, medical ethics and precision oncology. He is the Global Head of Clinical Research at Caris Life Sciences and works as Research Faculty at West Cancer Center where he served as the Director of Research from 2014 to 2021. He is also Professor in the Division of Epidemiology at the University of Memphis School of Public Health. Dr. VanderWalde has extensive experience in clinical research, including the design and conduct of clinical trials, results reporting, regulatory filing and interactions between investigators and the pharmaceutical industry.
Muh Geot Wong MBBS, MRCP, PhD
Dr. Wong’s research interest is in understanding the pathomechanism of kidney fibrosis and he has actively promoted the development of both clinical and pre-clinical research in delaying CKD progression in diabetic nephropathy, IgA nephropathy, and management of cardiovascular complications associated with CKD. He is a renal physician and Senior Staff Specialist at the Royal North Shore Hospital, Sydney; Senior clinical Lecturer of University of Sydney and University of NSW; and Senior Research Fellow, Renal & Metabolic Division for The George Institute and at the Kolling Institute.